Drugs /

skb264

Back to Drugs List

Overview

NCI Definition [1]:
An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated to an as of yet undisclosed toxin, with potential antineoplastic activity. Upon administration of the anti-TROP2 ADC SKB264, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the undisclosed toxin exerts, through an as of yet not disclosed mechanism of action, its cytotoxic effect. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues; its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.

Clinical Trials

View Clinical Trials for skb264

Skb264 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating skb264, 1 is phase 1/phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for skb264 clinical trials.

Breast carcinoma, gastric adenocarcinoma, and malignant ovarian epithelial tumor are the most common diseases being investigated in skb264 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Skb264
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating skb264 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
skb 264, skb-264, adc skb264, anti-trop2 antibody-drug conjugate skb264
NCIT ID [1]:
C166409

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.